Tacalyx, the first company created from French VC Kurma’s new Munich office, signals continued interest in tumor-associated carbohydrate antigens (TACAs), the targeting of sugars up-regulated in cancers. Kurma Partners opened the German office early this year with the intention of creating start-ups based on academic research in that country, which the firm believes has been underserved by VCs (see “Kurma’s Munich Move”). [...]